HBK Investments L P trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,731 shares of the company’s stock after selling 6,269 shares during the quarter. HBK Investments L P’s holdings in IDEXX Laboratories were worth $2,460,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of IDXX. Cabot Wealth Management Inc. grew its holdings in IDEXX Laboratories by 3.5% during the fourth quarter. Cabot Wealth Management Inc. now owns 9,050 shares of the company’s stock valued at $1,415,000 after purchasing an additional 309 shares during the period. Norinchukin Bank The grew its holdings in IDEXX Laboratories by 6.2% during the third quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock valued at $1,010,000 after purchasing an additional 379 shares during the period. Cubist Systematic Strategies LLC grew its holdings in IDEXX Laboratories by 5.3% during the third quarter. Cubist Systematic Strategies LLC now owns 7,662 shares of the company’s stock valued at $1,191,000 after purchasing an additional 384 shares during the period. Catalyst Capital Advisors LLC grew its holdings in IDEXX Laboratories by 2.3% during the fourth quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock valued at $2,752,000 after purchasing an additional 400 shares during the period. Finally, Synovus Financial Corp grew its holdings in IDEXX Laboratories by 18.1% during the third quarter. Synovus Financial Corp now owns 2,655 shares of the company’s stock valued at $408,000 after purchasing an additional 406 shares during the period. 87.07% of the stock is owned by institutional investors.
Several brokerages have weighed in on IDXX. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 7th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price target for the company in a report on Monday, February 5th. Bank of America raised their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Piper Jaffray Companies raised their price target on IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $210.00 price target on shares of IDEXX Laboratories in a report on Monday, January 29th. One analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $194.00.
In related news, Director William T. End sold 4,000 shares of IDEXX Laboratories stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total transaction of $737,920.00. Following the completion of the sale, the director now owns 41,256 shares of the company’s stock, valued at $7,610,906.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel M. Junius sold 2,974 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $190.06, for a total value of $565,238.44. Following the sale, the director now directly owns 5,602 shares of the company’s stock, valued at approximately $1,064,716.12. The disclosure for this sale can be found here. Insiders sold 91,736 shares of company stock valued at $16,193,502 over the last ninety days. Corporate insiders own 2.77% of the company’s stock.
IDEXX Laboratories stock opened at $204.73 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $146.09 and a twelve month high of $207.14. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. The company has a market capitalization of $17,836.65, a price-to-earnings ratio of 64.79, a PEG ratio of 2.51 and a beta of 0.58.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. During the same period last year, the company earned $0.58 earnings per share. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. research analysts anticipate that IDEXX Laboratories, Inc. will post 4.11 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Shares Sold by HBK Investments L P” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://ledgergazette.com/2018/03/19/idexx-laboratories-inc-idxx-shares-sold-by-hbk-investments-l-p.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.